

18th June 2024

To,

The Secretary
Bombay Stock Exchange Limited
Phiroze Jeejeebhoy Towers
Dalal Street Mumbai 400 001

Scrip Code: 500674

The Secretary National Stock Exchange of India Limited Exchange Plaza, 5th Floor

Plot No. C/1, G Block

Bandra-Kurla Complex, Bandra East,

Mumbai 400 050 **Symbol:** SANOFI

Ref: Disclosure under Regulation 30 of the Securities and Exchange Board of India

(Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

("SEBI (LODR) Regulations").

Sub: Allotment of shares by Sanofi Consumer Healthcare India Limited pursuant to the

Scheme of Arrangement ("Scheme") between Sanofi India Limited and Sanofi

Consumer Healthcare India Limited.

Dear Sir/Madam,

This is in furtherance of our communication dated 1st June 2024 under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI LODR") and communication dated 3rd June 2024 under Regulation 42 of the SEBI LODR, in connection with the Scheme of Arrangement between Sanofi India Limited ("Demerged Company") and its wholly owned subsidiary, Sanofi Consumer Healthcare India Limited ("Resulting Company") for the demerger of the consumer healthcare undertaking of the Demerged Company with and into the Resulting Company. In furtherance thereof, we now wish to inform you that in terms of Clause 3.3 of the Scheme, the Resulting Company at its board meeting dated 17th June 2024, has approved the allotment of 2,30,30,622 (Two Crore Thirty Lakhs Thirty Thousand Six Hundred Twenty Two) shares of the Resulting Company to the shareholders of the Demerged Company whose names were recorded in the BENPOS statement of the Demerged Company on 13th June 2024, i.e., the Record Date (as defined in the Scheme), which date was mutually agreed by the board of directors of the Demerged Company and the Resulting Company.

This is for your information and records.

Thanking you,

Yours faithfully

For Sanofi India Limited

Radhika Shah Head of Legal and Company Secretary